[go: up one dir, main page]

DeForge et al., 1991 - Google Patents

Synthesis and evaluation of radioiodinated cholesteryl ethers as lipoprotein probes

DeForge et al., 1991

Document ID
9815352869599366357
Author
DeForge L
Ruyan M
Schwendner S
Newton R
Counsell R
Publication year
Publication venue
Bioconjugate Chemistry

External Links

Snippet

Two novel cholesteryl ether derivatives were synthesized and radioiodinated:(1)[125I] cholesteryl m-iodobenzyl ether (125I-CIBE) and (2)[126I] cholesteryl 12-(m-iodophenyl) dodecyl ether (126I-CIDE). These radioiodinated ethers were incorporated into low-density …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors

Similar Documents

Publication Publication Date Title
Glass et al. Tissue sites of degradation of apoprotein AI in the rat.
Stein et al. Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether
Glass et al. Uptake of high-density lipoprotein-associated apoprotein AI and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro.
Fisher et al. The metabolism of apolipoprotein B in subjects with hypertriglyceridemia and polydisperse LDL.
Counsell et al. Tumor localizing agents. IX. Radioiodinated cholesterol
Barter et al. In vitro exchanges of esterified cholesterol between serum lipoprotein fractions: studies of humans and rabbits
Shepherd et al. Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.
Schwartz et al. Central role of high density lipoprotein in plasma free cholesterol metabolism
Harrison et al. Hepatic uptake and metabolism of chylomicron retinyl esters: probable role of plasma membrane/endosomal retinyl ester hydrolases
Srinivasan et al. Low density lipoprotein retention by aortic tissue: contribution of extracellular matrix
Camejo et al. The very low density lipoproteins of cholesterol-fed rabbits: A study of their structure and in vivo changes in plasma
Daugherty et al. Loci of catabolism of beta-very low density lipoprotein in vivo delineated with a residualizing label, 125I-dilactitol tyramine.
DeForge et al. Synthesis and evaluation of radioiodinated cholesteryl ethers as lipoprotein probes
Breslow et al. Lipoprotein regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in rat liver cell cultures.
Pietzsch et al. Fluorine-18 radiolabeling of low-density lipoproteins: a potential approach for characterization and differentiation of metabolism of native and oxidized low-density lipoproteins in vivo
Nakandakare et al. Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion: studies in normolipidemic and hyperlipidemic subjects.
Seevers et al. Potential organ-or tumor-imaging agents. 22. Acyl-labeled cholesterol esters
Goodman et al. The divergent metabolic fate of ether analogs of cholesteryl and retinyl esters after injection in lymph chylomicrons into rats
Deforge et al. Comparison of methods for incorporating a radioiodinated residualizing cholesteryl ester analog into low density lipoprotein
Alam et al. The mass uptake of cholesterol ester from low density lipoproteins by cultured smooth muscle and adventitial cells of human aortas.
EP1287016B1 (en) Radioimaging probes and the use thereof
Counsell et al. Lipoproteins as carriers for organ-imaging radiopharmaceuticals
Stein et al. Interaction between macrophages and mesenchymal cells Effect of LDL-or HDL-containing media, added to cholesteryl ester-loaded macrophages, on cholesterol esterification in mesenchymal cells
Atsma et al. Potential of 99mTc-LDLs labeled by two different methods for scintigraphic detection of experimental atherosclerosis in rabbits.
Sodhi et al. Labeling plasma lipoproteins with radioactive cholesterol